• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced it has successfully licensed exclusive worldwide development and commercialization rights to the GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class approach to modifying potent cancer-targeting immune cells to optimize the likelihood of deep r

WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS' NexGenAI Affiliates Network "NexGen" and NUBURU, Inc. "NUBURU" (NYSE:BURU), a leading innovator in high-power blue laser technology. This collaboration is a pivotal component of COEPTIS' strategic position in technology and Artificial Intelligence and NUBURU's comprehensive Transformation Plan, spearheaded by Executive Chairman Alessandro Zamboni, aimed at enhancing operational efficiency and revamping the company's business model entering defense

NUBURU, Inc. (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology announced its strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ:COEP), an innovative provider of artificial intelligence and robotics solutions. This collaboration is a pivotal component of NUBURU's comprehensive Transformation Plan, spearheaded by Executive Chairman Alessandro Zamboni, aimed at enhancing operational efficiency and revamping the company's business model. The Transformation Plan, by leveraging the existing know-how regarding blue-laser technology and additional expertise to be brought by the new management team, is specifically designed to l

WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS' NexGenAI Affiliates Network and Arketyp Valu, a prominent developer within the open-source Verus Project, which has recently achieved a market capitalization exceeding $500 million. This collaboration aims to integrate NexGenAI's advanced digital marketing solutions into the highly anticipated ValuSocial platform, harnessing the power of Verus Coin and its scalable Public Blockchains as a Service (PBaaS). The innovative ValuSocial platfo

WEXFORD, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) --  COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is thrilled to announce a partnership between COEPTIS' NexGenAI Affiliates Network and MarketLeverage, a leading digital advertising firm and affiliate network. This collaboration aims to redefine affiliate marketing by integrating cutting-edge AI technology with performance-based strategies. With MarketLeverage's extensive industry expertise and NexGenAI Affiliates Network's innovative AI-powered platform, this collaboration will empower affiliates, brands, and marketers with advanced automation, da

WEXFORD, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the launch of COEP Venture Group, a newly established investment arm dedicated to funding and accelerating technology startups specializing in Artificial Intelligence (AI), Robotic Process Automation (RPA), and AI Agents. COEP Venture Group aims to identify, invest in, and support high-potential startups shaping the future of automation, intelligent systems, and AI-driven enterprise solutions.

WEXFORD, Pa., Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the successful closure of an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million. This significant achievement highlights investor confidence in Coeptis' innovative therapeutic solutions and its strategic pivot towards technology-driven growth.

Rebranding Signals Strategic Shift Beyond Biopharmaceuticals, Highlights Commitment to Technology, Artificial Intelligence and Shareholder Value WEXFORD, Pa., Jan. 30, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce its rebranding to COEPTIS, marking a transformative shift in its business strategy. This pivotal change reflects our commitment to expanding beyond biopharmaceuticals and embracing diverse growth opportunities in technology-driven sectors.With the establishment of our new Technology Di

Coeptis Harnesses AI Advances and Blockchain Initiatives to Drive Operational Efficiency and Strategic Growth WEXFORD, Pa., Jan. 23, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the expansion of its technological initiatives to include cutting-edge artificial intelligence and innovative blockchain solutions. Following the successful launch of its Technology Division and the intro

WEXFORD, Pa., Jan. 22, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it has regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"), as required by the Nasdaq Hearings Panel's decision of September 17, 2024. "We thank the Nasdaq Hearings Panel for approving our request," said Coeptis' Chief Executive Officer Dave Mehalick. "Regaining compliance with Nasdaq's listing stand

SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat

Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.

15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in